<Suppliers Price>

PF-00299804

Names

[ CAS No. ]:
1042385-75-0

[ Name ]:
PF-00299804

[Synonym ]:
(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide hydrate (1:1)
Dacomitinib [USAN:INN]
2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-, hydrate (1:1)
(2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide, hydrate (1:1)
UNII-5092U85G58
2-Butenamide,N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-,hydrate (1:1),(2E)
Dacomitinib
dacomitinib hydrate
Dacomitinib hydrate (JAN)
(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide monohydrate
Dacomitinib monohydrate
(2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate
PF-00299804

Biological Activity

[Description]:

Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> JAK/STAT Signaling >> EGFR
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[References]

[1]. Lau SCM, et al. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs. 2019 Jun;79(8):823-831.  

Chemical & Physical Properties

[ Molecular Formula ]:
C24H27ClFN5O3

[ Molecular Weight ]:
487.95

[ Exact Mass ]:
487.178650

[ PSA ]:
92.10000

[ LogP ]:
5.75120

Safety Information

[ Hazard Codes ]:
Xi

Related Compounds